Browse > Article
http://dx.doi.org/10.14348/molcells.2017.2285

Down-Regulation of MicroRNA-210 Confers Sensitivity towards 1'S-1'-Acetoxychavicol Acetate (ACA) in Cervical Cancer Cells by Targeting SMAD4  

Phuah, Neoh Hun (Institute of Biological Sciences (Genetics and Molecular Biology), Faculty of Science, University of Malaya)
Azmi, Mohamad Nurul (Centre for Natural Product Research and Drug Discovery (CENAR), Department of Chemistry, Faculty of Science, University of Malaya)
Awang, Khalijah (Centre for Natural Product Research and Drug Discovery (CENAR), Department of Chemistry, Faculty of Science, University of Malaya)
Nagoor, Noor Hasima (Institute of Biological Sciences (Genetics and Molecular Biology), Faculty of Science, University of Malaya)
Publication Information
Molecules and Cells / v.40, no.4, 2017 , pp. 291-298 More about this Journal
Abstract
MicroRNAs (miRNAs) are short non-coding RNAs that regulate genes posttranscriptionally. Past studies have reported that miR-210 is up-regulated in many cancers including cervical cancer, and plays a pleiotropic role in carcinogenesis. However, its role in regulating response towards anti-cancer agents has not been fully elucidated. We have previously reported that the natural compound 1'S-1'-acetoxychavicol acetate (ACA) is able to induce cytotoxicity in various cancer cells including cervical cancer cells. Hence, this study aims to investigate the mechanistic role of miR-210 in regulating response towards ACA in cervical cancer cells. In the present study, we found that ACA down-regulated miR-210 expression in cervical cancer cells, and suppression of miR-210 expression enhanced sensitivity towards ACA by inhibiting cell proliferation and promoting apoptosis. Western blot analysis showed increased expression of mothers against decapentaplegic homolog 4 (SMAD4), which was predicted as a target of miR-210 by target prediction programs, following treatment with ACA. Luciferase reporter assay confirmed that miR-210 binds to sequences in 3'UTR of SMAD4. Furthermore, decreased in SMAD4 protein expression was observed when miR-210 was overexpressed. Conversely, SMAD4 protein expression increased when miR-210 expression was suppressed. Lastly, we demonstrated that overexpression of SMAD4 augmented the anti-proliferative and apoptosis-inducing effects of ACA. Taken together, our results demonstrated that down-regulation of miR-210 conferred sensitivity towards ACA in cervical cancer cells by targeting SMAD4. These findings suggest that combination of miRNAs and natural compounds could provide new strategies in treating cervical cancer.
Keywords
apoptosis; cervical cancer; microRNA; natural compound; SMAD4;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Qin, Q., Furong, W., and Baosheng, L. (2014). Multiple functions of hypoxia-regulated miR-210 in cancer. J. Exp. Clin. Cancer Res. 33, 50.   DOI
2 Rao, Q., Shen, Q., Zhou, H., Peng, Y., Li, J., and Lin, Z. (2012). Aberrant microRNA expression in human cervical carcinomas. Med. Oncol. 29, 1242-1248.   DOI
3 Tang, X., Chen, L., Yan, X., Li, Y., Xiong, Y., and Zhou, X. (2015). Overexpression of miR-210 is associated with poor prognosis of acute myeloid leukemia. Med. Sci. Monit. 21, 3427-3433.   DOI
4 Torre, L.A., Bray, F., Siegel, R.L., Ferlay, J., Lortet-Tieulent, J., and Jemal, A. (2015). Global cancer statistics, 2012. CA Cancer J. Clin. 65, 87-108.   DOI
5 Wu, S., Huang, S., Ding, J., Zhao, Y., Liang, L., Liu, T., Zhan, R., and He, X. (2010). Multiple microRNAs modulate p21Cip1/Waf1 expression by directly targeting its 3' untranslated region. Oncogene 29, 2302-2308.   DOI
6 Yang, W., Sun, T., Cao, J., Liu, F., Tian, Y., and Zhu, W. (2012). Downregulation of miR-210 expression inhibits proliferation, induces apoptosis and enhances radiosensitivity in hypoxic human hepatoma cells in vitro. Exp. Cell Res. 318, 944-954.   DOI
7 Yang, W., Wei, J., Sun, T., and Liu, F. (2013). Effects of knockdown of miR-210 in combination with ionizing radiation on human hepatoma xenograft in nude mice. Radiat. Oncol. 8, 102.   DOI
8 Yu, S.L., Lee, D.C., Son, J.W., Park, C.G., Lee, H.Y., and Kang, J. (2013). Histone deacetylase 4 mediates SMAD family member 4 deacetylation and induces 5-fluorouracil resistance in breast cancer cells. Oncol. Rep. 30, 1293-1300.   DOI
9 Zhang, B., Zhang, B., Chen, X., Bae, S., Singh, K., Washington, M.K., and Datta, P.K. (2014). Loss of Smad4 in colorectal cancer induces resistance to 5-fluorouracil through activating Akt pathway. Br. J. Cancer 110, 946-957.   DOI
10 Zhang, B., Leng, C., Wu, C., Zhang, Z., Dou, L., Luo, X., Zhang, B., and Chen, X. (2016). Smad4 sensitizes colorectal cancer to 5- fluorouracil through cell cycle arrest by inhibiting the PI3K/Akt/CDC2/survivin cascade. Oncol. Rep. 35, 1807-1815.   DOI
11 Camps, C., Buffa, F.M., Colella, S., Moore, J., Sotiriou, C., Sheldon, H., Harris, A.L., Gleadle, J.M., and Ragoussis, J. (2008). hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin. Cancer Res. 14, 1340-1348.   DOI
12 Awang, K., Azmi, M.N., Aun, L.I., Aziz, A.N., Ibrahim, H., and Nagoor, N.H. (2010). The apoptotic effect of 1's-1'-acetoxychavicol acetate from Alpinia conchigera on human cancer cells. Molecules 15, 8048-8059.   DOI
13 Baez, A., Cantor, A., Fonseca, S., Marcos-Martinez, M., Mathews, L.A., Muro-Cacho, C.A., and Munoz-Antonia, T. (2005). Differences in Smad4 expression in human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck squamous cell carcinoma. Clin. Cancer Res. 11, 3191-3197.   DOI
14 Baldus, S.E., Schwarz, E., Lohrey, C., Zapatka, M., Landsberg, S., Hahn, S.A., Schmidt, D., Dienes, H.P., Schmiegel, W.H., and Schwarte-Waldhoff, I. (2005). Smad4 deficiency in cervical carcinoma cells. Oncogene 24, 810-819.   DOI
15 Cheng, H., Fertig, E.J., Ozawa, H., Hatakeyama, H., Howard, J.D., Perez, J., Considine, M., Thakar, M., Ranaweera, R., Krigsfeld, G., et al. (2015). Decreased SMAD4 expression is associated with induction of epithelial-to-mesenchymal transition and cetuximab resistance in head and neck squamous cell carcinoma. Cancer Biol. Ther. 16, 1252-1258.   DOI
16 Gottesman, M.M. (2002). Mechanisms of cancer drug resistance. Annu. Rev. Med. 53, 615-627.   DOI
17 Crafton, S.M., and Salani, R. (2016). Beyond chemotherapy: an overview and review of targeted therapy in cervical cancer. Clin. Ther. 38, 449-458.   DOI
18 Cragg, G.M., and Newman, D.J. (2005). Plants as a source of anticancer agents. J. Ethnopharmacol. 100, 72-79.   DOI
19 Dang, K., and Myers, K.A. (2015). The role of hypoxia-induced miR- 210 in cancer progression. Int. J. Mol. Sci. 16, 6353-6372.   DOI
20 Greither, T., Grochola, L.F., Udelnow, A., Lautenschlager, C., Wurl, P., and Taubert, H. (2010). Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int. J. Cancer 126, 73-80.   DOI
21 Hernanda, P.Y., Chen, K., Das, A.M., Sideras, K., Wang, W., Li, J., Cao, W., Bots, S.J., Kodach, L.L., de Man, R.A., et al. (2015). SMAD4 exerts a tumor-promoting role in hepatocellular carcinoma. Oncogene 34, 5055-5068.   DOI
22 Ho, C.S., Yap, S.H., Phuah, N.H., In, L.L., and Hasima, N. (2014). MicroRNAs associated with tumour migration, invasion and angiogenic properties in A549 and SK-Lu1 human lung adenocarcinoma cells. Lung Cancer 83, 154-162.   DOI
23 Jung, E.J., Santarpia, L., Kim, J., Esteva, F.J., Moretti, E., Buzdar, A.U., Di Leo, A., Le, X.F., Bast, R.C., Jr., Park, S.T., et al. (2012). Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer 118, 2603-2614.   DOI
24 Liang, Z., Li, S., Xu, X., Xu, X., Wang, X., Wu, J., Zhu, Y., Hu, Z., Lin, Y., Mao, Y., et al. (2015). MicroRNA-576-3p inhibits proliferation in bladder cancer cells by targeting cyclin D1. Mol. Cells 38, 130-137.   DOI
25 Kim, Y., Kim, H., Park, D., and Jeoung, D. (2015). miR-335 targets SIAH2 and confers sensitivity to anti-cancer drugs by increasing the expression of HDAC3. Mol. Cells 38, 562-572.   DOI
26 Klein-Scory, S., Zapatka, M., Eilert-Micus, C., Hoppe, S., Schwarz, E., Schmiegel, W., Hahn, S.A., and Schwarte-Waldhoff, I. (2007). Highlevel inducible Smad4-reexpression in the cervical cancer cell line C4-II is associated with a gene expression profile that predicts a preferential role of Smad4 in extracellular matrix composition. BMC Cancer 7, 209.   DOI
27 Kloth, J.N., Kenter, G.G., Spijker, H.S., Uljee, S., Corver, W.E., Jordanova, E.S., Fleuren, G.J., and Gorter, A. (2008). Expression of Smad2 and Smad4 in cervical cancer: absent nuclear Smad4 expression correlates with poor survival. Mod. Pathol. 21, 866-875.   DOI
28 Lagos-Quintana, M., Rauhut, R., Lendeckel, W., and Tuschl, T. (2001). Identification of novel genes coding for small expressed RNAs. Science 294, 853-858.   DOI
29 Lee, S., Cho, Y.S., Shim, C., Kim, J., Choi, J., Oh, S., Kim, J., Zhang, W., and Lee, J. (2001). Aberrant expression of Smad4 results in resistance against the growth-inhibitory effect of transforming growth factor-beta in the SiHa human cervical carcinoma cell line. Int. J. Cancer 94, 500-507.   DOI
30 Liu, N., Yu, C., Shi, Y., Jiang, J., and Liu, Y. (2015). SMAD4 expression in breast ductal carcinoma correlates with prognosis. Oncol. Lett. 10, 1709-1715.   DOI
31 Livak, K.J., and Schmittgen, T.D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method Methods 25, 402-408.   DOI
32 Lou, M., Jia, Y., Duan, Z., Wu, J., Luo, M., and Wang, Y. (2016). Correlation between human papillomavirus and microRNA-210 in hypoxia-associated human cervical cancer. Int. J. Clin. Exp. Pathol. 9, 1148-1157.
33 Monk, B.J., Sill, M.W., McMeekin, D.S., Cohn, D.E., Ramondetta, L.M., Boardman, C.H., Benda, J., and Cella, D. (2009). Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 27, 4649-4655.   DOI
34 Martinez, I., Gardiner, A.S., Board, K.F., Monzon, F.A., Edwards, R.P., and Khan, S.A. (2008). Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells. Oncogene 27, 2575-2582.   DOI
35 Millimouno, F.M., Dong, J., Yang, L., Li, J., and Li, X. (2014). Targeting apoptosis pathways in cancer and perspectives with natural compounds from mother nature. Cancer Prev. Res. 7, 1081-1107.   DOI
36 Miyaki, M., Iijima, T., Konishi, M., Sakai, K., Ishii, A., Yasuno, M., Hishima, T., Koike, M., Shitara, N., Iwama, T., et al. (1999). Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis. Oncogene 18, 3098-3103.   DOI
37 Phuah, N.H., In, L.L., Azmi, M.N., Ibrahim, H., Awang, K., and Nagoor, N.H. (2013). Alterations of microRNA expression patterns in human cervical carcinoma cells (Ca Ski) toward 1'S-1'- acetoxychavicol acetate and cisplatin. Reprod. Sci. 20, 567-578.   DOI
38 Othman, N., In, L.L., Harikrishna, J.A., and Hasima, N. (2013). Bcl-xL silencing induces alterations in hsa-miR-608 expression and subsequent cell death in A549 and SK-LU1 human lung adenocarcinoma cells. PLoS One 8, e81735.   DOI
39 Papageorgis, P., Cheng, K., Ozturk, S., Gong, Y., Lambert, A.W., Abdolmaleky, H.M., Zhou, J.R., and Thiagalingam, S. (2011). Smad4 inactivation promotes malignancy and drug resistance of colon cancer. Cancer Res. 71, 998-1008.   DOI
40 Phuah, N.H., and Nagoor, N.H. (2014). Regulation of microRNAs by natural agents: new strategies in cancer therapies. Biomed. Res. Int. 2014, 804510.